The importance of pain as a presenting symptom of breast cancer has been assessed in a series of 240 patients with operable breast cancer over four years. From an analysis of the case histories of 36 patients the diagnosis proved difficult in one-quarter of the cancers. This is explained by the high incidence of subclinical and lobular carcinoma in the group. Cancer must be seriously considered as a diagnosis in patients presenting with welllocalised breast pain of recent onset. These patients should be followed for at least one year after the onset of the pain before cancer is confidently excluded.
Introduction
At present pain tends to be disregarded in the diagnosis of breast cancer. In fact, it is often said that the presence of pain excludes this diagnosis; the reasons given are its reported infrequency in operable disease,' its variability,2 and the common occurrence of the symptom in benign breast disease.3 Our finding that onethird of patients with subclinical breast cancers presented with pain4 has prompted a review of early breast cancers in which pain was a presenting symptom.
Patients and methods
At their first visit to the breast clinic in Cardiff all patients complete a questionnaire, which aims at systematic and complete collection of relevant information. Pain pathological group is shown in table IV. More than one sign was present in some cases. In 10 patients cancer was not recognised as such on initial mammography. Three were cases of subclinical lobular carcinoma. One had a vague architectural deformity, only recognised in retrospect five months later when it became more pronounced on follow-up radiographs. Of two patients who had no radiological signs of malignancy, one developed a palpable nodule which underwent biopsy nine months after presentation, and one underwent biopsy because the vague thickening palpated at first visit persisted. Seven invasive ductal cancers were not diagnosed by radiography; one had a mass interpreted as periductal mastitis and two had incidental benign calcifications. In the one patient who had no clinical or radiological signs on presentation, a discrete mass was palpated four months later at the site of the presenting complaint of continuous pain. To date, the mean follow-up time of patients in this series is 7-5 years, ranging from 5 to 10 with a median of eight years. Table V shows the outcome so far for each TNM stage at presentation. Discussion Pain is the commonest breast symptom.6 Usually it reflects normal physiological processes or benign breast disease. The present series shows that this is not always a safe assumption, as has been shown7 (although often ignored) in previous series. The incidence of pain as the presenting symptom in such series ranges between 5 % and 17%'"1 figures comparable to our finding that 150% of cases of operable breast cancer have pain as one of their presenting complaints, and 7% complain of mastalgia alone. This series also confirms that pain in breast cancer can lead to early diagnosis.'1 12 This is particularly true for those patients presenting with pain alone, in whom onethird of cancers are subclinical-that is, they are not detectable by palpation (table I) . By coincidence, one-third of subclinical cancers present with pain.4 For the whole series 25% of painful operable cancers are T, N, M, and 15%// subclinical.
We have been unable to correlate any descriptive terms used by patients for their pain with any definable features of the tumours.' Unlike Corry, however, we have found that some patients volunteered the information that the pain radiated to the axilla or arm, a common feature of pain in benign breast disease. Contrary to previous teaching, therefore, axillary radiation cannot be assumed to exclude malignancy. Despite this radiation outside the breast, the pain within the breast tends to be well localised and persistent.
About half the patients studied, both those with mastalgia as their only complaint and the group as a whole, were premenopausal at the time of presentation. This has the important implication that mastalgia can be a sign of malignancy in premenopausal as in postmenopausal women. Similarly, since breast pain is so much less common after the menopause, its development at this time must be given particular attention.
The false-negative rate by mammography in Cardiff is 8-10%. Among the 36 patients studied, 250, of malignancies were not recognised on the initial mammogram; one-third of these were not even suspected clinically. Half the lobular cancers were not detected mammographically; this neoplasm is well known for eluding radiologists.1' 14 With the other tumours there was a particular low incidence of microcalcification, which undoubtedly played an important part in the low diagnostic rate. We have no explanation for it, apart from the high incidence of very early tumours.
Six (16%) cases of lobular carcinoma, in 36 breast cancers, is a high proportion. In the Cardiff mastectomy trial'5 the local incidence was about 2-5°0, of all stage I and II breast cancers. This suggests that lobular carcinoma in particular causes pain, which is important because of the difficulty of radiological diagnosis"3 and histological diagnosis by frozen section histology,'6 particularly when the cancer is preinvasive. Because of these difficulties women who present with mastalgia, especially over the age of 30 years, '7 I1 should be investigated at least as thoroughly as if they complained of a lump or a nipple discharge. If localised pain persists after negative investigation, assessment should be repeated for at least 12 months.
In the present study the figures were too small and the followup period too short for accurate analysis. The results stage for stage probably do not differ from wider series. They do strongly suggest, however, that if attention is paid to breast pain a high proportion of early tumours are diagnosed. In this way the advantages of earlier presentation can be exploited.
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